197 related articles for article (PubMed ID: 19066329)
1. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
Kim DH; Kamel-Reid S; Chang H; Sutherland R; Jung CW; Kim HJ; Lee JJ; Lipton JH
Haematologica; 2009 Jan; 94(1):135-9. PubMed ID: 19066329
[TBL] [Abstract][Full Text] [Related]
2. Large granular lymphocytosis during dasatinib therapy.
Qiu ZY; Xu W; Li JY
Cancer Biol Ther; 2014 Mar; 15(3):247-55. PubMed ID: 24352048
[TBL] [Abstract][Full Text] [Related]
3. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas S
Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
[TBL] [Abstract][Full Text] [Related]
5. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
Watanabe N; Takaku T; Takeda K; Shirane S; Toyota T; Koike M; Noguchi M; Hirano T; Fujiwara H; Komatsu N
Int J Hematol; 2018 Dec; 108(6):588-597. PubMed ID: 30151740
[TBL] [Abstract][Full Text] [Related]
7. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
[TBL] [Abstract][Full Text] [Related]
8. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
[TBL] [Abstract][Full Text] [Related]
9. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Valent JN; Schiffer CA
Leuk Res; 2011 Jan; 35(1):e1-3. PubMed ID: 20888043
[No Abstract] [Full Text] [Related]
11. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
Tanaka H; Nakashima S; Usuda M
Int J Hematol; 2012 Sep; 96(3):308-19. PubMed ID: 22767140
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib-induced spleen contraction leads to transient lymphocytosis.
Marcos-Jiménez A; Carvoeiro DC; Ruef N; Cuesta-Mateos C; Roy-Vallejo E; Gómez-García de Soria V; Laganá C; Del Campo L; Zubiaur P; Villapalos-García G; Abad-Santos F; Stein JV; Muñoz-Calleja C
Blood Adv; 2023 Jun; 7(11):2418-2430. PubMed ID: 36583674
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
Nagata Y; Ohashi K; Fukuda S; Kamata N; Akiyama H; Sakamaki H
Int J Hematol; 2010 Jun; 91(5):799-807. PubMed ID: 20405252
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.
Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
Cancer Sci; 2018 Jan; 109(1):182-192. PubMed ID: 29058817
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
17. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
18. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.
Lee SJ; Jung CW; Kim DY; Lee KH; Sohn SK; Kwak JY; Kim HJ; Kim IH; Park S; Kim DH
Am J Hematol; 2011 Apr; 86(4):346-50. PubMed ID: 21442637
[TBL] [Abstract][Full Text] [Related]
19. Large granular lymphocytosis induced by dasatinib.
Fernandes F; Ramalho R; Barreira R; Silveira M; Bain BJ
Am J Hematol; 2021 Mar; 96(3):395-396. PubMed ID: 32757492
[No Abstract] [Full Text] [Related]
20. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
Kreutzman A; Ladell K; Koechel C; Gostick E; Ekblom M; Stenke L; Melo T; Einsele H; Porkka K; Price DA; Mustjoki S; Seggewiss R
Leukemia; 2011 Oct; 25(10):1587-97. PubMed ID: 21647156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
